Guided miss: execution on plan, but NJ Bio drag and vague recovery timeline crimp credibility

Revenue ₹422.3 Cr (-23.1% YoY), as warned, matching prior call guidance

Sapala added ₹274 Cr revenue at 2.5x YoY, maintained strong EBITDA margin

NJ Bio ₹350 Cr revenue with -₹328 Cr EBITDA loss (-94% margin), not improving; biotech funding concerns cited

One molecule restocking order "spread over 2 years" Q4 FY27 → FY28; second destocking molecule timing uncertain

10 Phase 3 molecules in pipeline, but "some may not get approval"; recent deliveries bimodal (fresh + maturing); realistic >50% approval rate

Standalone (₹3,599 Cr) at 9.2% margin vs 30%+ historical; largely because high-margin CDMO declined 38.7%, low-margin specialty chem fell 34.7%

Post-acquisition full consolidation of loss-making NJ Bio (₹350 Cr revenue, -₹328 Cr EBITDA) pulls consolidated margin from 9.2% (standalone) to 2.2%. Not explicitly called out as new drag.

Umang explicitly calls it "aspiration", says "may be a little bit away from it over the next 3-4 years", defers granularity to December. Effectively downgraded from committed target.

Sapala 2.5x growth Q1; oligonucleotide shipments under orphan drug program commenced; amidites facility commercialization planned. Umang sees 3–4 year doubling potential, not quantified.

Reaffirmed prior guidance that H2 will show growth vs H1; supported by restocking + Phase 3 conversions + utilization recovery. Still on track vs prior call.

CDMO (small molecule + ADCs + oligonucleotides) expected doubling in 3–4 years. API+ CAGR business, 30–40% of potential. AgChem/Spec Chem improving but early stage. No quantified FY27 guidance; H2 improvement expected.

Three-legged: (1) anchor customer relationships built over 7–10 years, (2) science envelope + analytical methods deepened by tech transfer, (3) cost in niche chemistry (not race-to-bottom). Peers moved faster; we catching up via widening existing relationships.

Yes, >50% approval rate expected; bimodal portfolio (fresh + maturing) explains recent revenue decline, supports future growth. Positioned well with customers already.

Umang: 3–4 year outlook suggests strong recovery. Himanshu: expect margins closer to 'previous year %' by end FY27, accelerate FY28 onwards. Difficult to articulate exact level now; operating leverage will drive recovery as revenue grows.

Umang: No granularity yet. Target now feels like an aspiration. May be 'a little bit away' over next 3–4 years. Will clarify by December.

One molecule secured, but order spread over 2 years. Second molecule progress awaited. Too early to quantify FY27 contribution. Clarity expected by Q2 call.

Gunjan: Yes, differentiated portfolio (CNS focus, control substances, innovator relationships). Margin profile "handsome", top tier in generic API space. Sustained growth via new product filings (7 in FY27, 9 last year). No exact %.

Umang: NJ Bio is a prime target. Lost biotech FTE customers due to funding concerns. Goal: match cost with revenue generation. Not yet cutting; first optimizing for utilization. Near-term NJ Bio expected to continue weighing on consolidated performance.

Supported by restocking orders, Phase 3 conversions (10 molecules, >50% approval hoped), Sapala scaling, utilization improvement. But timing of Phase 3 revenue is uncertain.

Q2FY27 expected "significantly better" than Q1; deliveries moved from Q1 now on track for Q2/Q3. Restocking and commercial OTIF support near-term revenue.

Given unusually low operating base in Q1, margin recovery will depend on revenue conversion, business mix, utilization. Management cautious on magnitude and timing.

Standalone 9.2% in Q1 vs 30%+ historical; CFO Himanshu non-specific on recovery path. No guidance on when consolidated margins recover to 20%+.

Focused on ADC, oligonucleotide, API+, specialty chemicals. Q1 capex ₹598 Cr; pace expected to continue. Strategic areas: amidites, ADC linkers, flow reactors.

NJ Bio -₹328 Cr EBITDA on ₹350 Cr revenue (94% negative margin). Biotech funding concerns caused FTE customer loss. Management committed to cost-to-revenue alignment but timeline unclear.

10 Phase 3 molecules in pipeline; management assumes >50% approval rate to feed future growth. But clinical failures, regulatory delays, or customer delays (not in hurry to switch suppliers) could derail timeline.

Prior ₹260 Cr destocking impact. One molecule restocking order secured but spread over 2 years (Q4 FY27 → FY28). Second molecule progress unknown. Limits near-term revenue recovery.

Intense competition; Umang claims moat is relationships (7–10 years to build), science envelope, niche chemistry. But peers (Divi's, Laurus) are larger and more established. Cohance is in early catch-up phase.

Management defers granularity on EBITDA margin recovery to H2/FY28. Standalone 9.2% in Q1 vs 30%+ historical; consolidated 2.2%. No clear path to 20%+ consolidated or when $1B revenue + historical margin combo materializes.

Prior ₹1B (approx $12B USD equivalent) FY30 revenue target now downgraded to "aspiration." Umang admits "may be a little bit away" and defers details to December. Signals management overcommitted or underestimated execution risk.